These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3053940)

  • 1. Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg.
    Duchene Marullaz P; Amiel M; Barbe R
    Int Angiol; 1988; 7(2 Suppl):25-32. PubMed ID: 3053940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg.
    Tsouderos Y
    Int Angiol; 1989; 8(4 Suppl):53-9. PubMed ID: 2698902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
    Geroulakos G; Nicolaides AN
    Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg.
    Tsouderos Y
    Z Kardiol; 1991; 80 Suppl 7():95-101. PubMed ID: 1792820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
    Amato C
    Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg.
    Laurent R; Gilly R; Frileux C
    Int Angiol; 1988; 7(2 Suppl):39-43. PubMed ID: 3053942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form.
    Cospite M; Dominici A
    Int Angiol; 1989; 8(4 Suppl):61-5. PubMed ID: 2698903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of the pharmacodynamic activity of daflon 500 mg].
    Amiel M; Barbe R
    Ann Cardiol Angeiol (Paris); 1998 Mar; 47(3):185-8. PubMed ID: 9772947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of clinical efficacy of a venotonic drug: lessons of a therapeutic trial with hemisynthesis diosmin in "heavy legs syndrome"].
    Carpentier PH; Mathieu M
    J Mal Vasc; 1998 Apr; 23(2):106-12. PubMed ID: 9608923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of a single daily dose of two capsules Cyclo 3 Fort in the morning versus a repeated dose of one capsule morning and noon. A one-month study.
    Boccalon H; Causse C; Yubero L
    Int Angiol; 1998 Sep; 17(3):155-60. PubMed ID: 9821028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of O-(beta-hydroxyethyl)-rutosides at high dosage in counteracting the unwanted activity of oral contraceptives on venous function.
    Cappelli R; Pecchi S; Oberhauser V; Forconi S; Di Perri T
    Int J Clin Pharmacol Res; 1987; 7(4):291-9. PubMed ID: 3596872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long term treatment with a venotropic drug. Results on efficacy and safety of Daflon 500 mg in chronic venous insufficiency.
    Guillot B; Guilhou JJ; de Champvallins M; Mallet C; Moccatti D; Pointel JP
    Int Angiol; 1989; 8(4 Suppl):67-71. PubMed ID: 2632651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic effectiveness of flavonoids illustrated by daflon 500 mg].
    Hitzenberger G
    Wien Med Wochenschr; 1997; 147(18):409-12. PubMed ID: 9454438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The chronobiology and clinical efficacy of Daflon in the treatment of chronic venous insufficiency].
    Menyhelyi G; Acsády G; Hetényi A; Dubeaux D; Radó G
    Ter Arkh; 1997; 69(4):46-8. PubMed ID: 9213959
    [No Abstract]   [Full Text] [Related]  

  • 15. [Controlled study of increasing venous tone in primary varicose veins by oral administration of Ruscus aculeatus and trimethylhespiridinchalcone].
    Weindorf N; Schultz-Ehrenburg U
    Z Hautkr; 1987 Jan; 62(1):28-38. PubMed ID: 3554800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders.
    Struckmann JR; Nicolaides AN
    Angiology; 1994 Jun; 45(6):419-28. PubMed ID: 8203767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vital capillaroscopy on microcirculation: pharmacodynamic activity of Daflon 500 mg in venous insufficiency.
    Balas P; Pagratis N
    Int Angiol; 1989; 8(4 Suppl):51-2. PubMed ID: 2632650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A double-blind study comparing the clinical efficacy of the preparation F-117 (hidrosmin) versus diosmin in the treatment of patients with peripheral venous disorders].
    Honorato Pérez J; Arcas Meca R
    Rev Med Univ Navarra; 1990; 34(2):77-9. PubMed ID: 2130425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency.
    Roztocil K; Stvrtinová V; Strejcek J
    Int Angiol; 2003 Mar; 22(1):24-31. PubMed ID: 12771852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The drug therapy of chronic venous insufficiency (a trial of the clinical use of the preparation Detralex)].
    Iablokov EG; Bogachev VIu; Domoradskaia AI
    Ter Arkh; 1996; 68(10):80-1. PubMed ID: 9026954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.